T2 Biosystems Stock Price, News & Analysis

T2 Biosystems (NASDAQ:TTOO) has signed an exclusive distribution agreement for its T2Dx® Instruments and panels in the Baltic Region, covering Lithuania, Latvia, and Estonia. This deal aims to enhance rapid detection of sepsis-causing pathogens, important due to the region's higher sepsis incidence compared to Western Europe. CEO John Sperzel emphasized the commitment to expanding globally, seeing growth potential in these markets. T2 Biosystems is focused on improving patient care and reducing treatment costs through its advanced diagnostics.

T2 Biosystems (NASDAQ:TTOO) announced its participation in the H.C. Wainwright Global Investment Conference scheduled for September 13, 2022, at 3:00 PM ET. The company specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance. Attendees can access a live and recorded webcast of the presentation from the company’s website. T2 Biosystems aims to enhance patient care with products powered by its proprietary T2 Magnetic Resonance technology, including the T2Dx® Instrument and various diagnostic panels for pathogens and antimicrobial resistance.

T2 Biosystems, a leader in rapid detection of sepsis pathogens and antibiotic resistance genes, will present at the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 11:30am ET. Interested parties can access a live webcast through the provided link. Post-event, an archived version will be available on the company's website. T2 Biosystems' innovative products include the T2Dx Instrument and various detection panels powered by proprietary T2 Magnetic Resonance technology, aiming to enhance patient care and reduce treatment costs.

T2 Biosystems, Inc. (TTOO) reported second-quarter 2022 revenue of $5.9 million, a 12% decline year-over-year. Product revenue fell by 30% to $2.6 million, mainly due to reduced T2SARS-CoV-2 sales. However, T2Dx Instrument contracts surged by 300%, with 12 contracts executed during the quarter. The company raised $27.4 million through an ATM facility, strengthening its balance sheet. Notably, the T2Lyme Panel received Breakthrough Device Designation from the FDA. Despite the revenue drop, T2 Biosystems maintains a 2022 revenue outlook of $28.0 to $31.0 million.

T2 Biosystems (NASDAQ:TTOO) is exploring the development of a rapid molecular diagnostic test for monkeypox, following the World Health Organization's declaration of a global emergency due to the virus. This initiative aims to enhance diagnosis and expedite treatment amidst the ongoing outbreak. The CEO emphasized the company's capability in developing new tests, having already engaged with the FDA and CDC regarding commercialization. The CDC currently holds the only FDA-cleared test for monkeypox, and T2 aims to facilitate increased diagnostic testing availability.

T2 Biosystems, Inc. (NASDAQ: TTOO) announced the issuance of inducement awards to twelve new employees on July 25, 2022. The awards, under the company's Inducement Award Plan, include options to purchase 225,000 shares of common stock at an exercise price of $0.137, equivalent to the closing price on the award date. The options will vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter. This initiative aims to enhance employee retention and attract talent while adhering to Nasdaq rules.

T2 Biosystems (NASDAQ:TTOO) will announce its second quarter 2022 financial results after market close on August 15, 2022. The announcement will be followed by a conference call at 4:30 p.m. ET, accessible via a live and archived webcast on the company's website. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance, aiming to enhance patient care while minimizing treatment costs. Their product lineup includes the T2Dx Instrument and various detection panels, backed by their proprietary T2 Magnetic Resonance technology.

T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced its participation in the Canaccord Genuity Annual Growth Conference in Boston on August 11, 2022, at 8:00am ET. The presentation will be accessible via a live and recorded webcast on the Company’s website. T2 Biosystems focuses on improving patient care with products like the T2Dx® Instrument and various detection panels, leveraging its proprietary T2 Magnetic Resonance technology. The company has a pipeline of future products aimed at detecting bacterial and fungal pathogens.

T2 Biosystems announces that its T2Lyme™ Panel has received FDA Breakthrough Device Designation. This designation aims to expedite the development of the T2Lyme Panel, which is a molecular diagnostic test for early detection of Lyme disease. The test can identify the bacteria responsible for Lyme disease directly from blood samples. Currently, there are no FDA-cleared tests for early detection, with existing methods often yielding false negatives. With approximately 476,000 cases of Lyme disease reported annually in the U.S., this test promises to improve patient outcomes significantly.